Roche Diagnostics Operations, Inc.

Boehringer Mannheim Gmbh

Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

Eucodis Bioscience Gmbh

F. Hoffmann-la Roche Ag

Eva Hoess

Erasmus Huber

Ronald Charles Hawley

Salvatore Joseph Salamone

John W Patterson

Mitali Ghoshal

Allan R Dorn

Christine Markert-Hahn

Christoph Seidel

Gerald F Sigler

Wilhelm Tischer

Raymond Hui

Beatus Ofenloch-Haehnle

Thomas Meier

Rainer Schmuck

Frederic Donie

Klaus Reichert

Bernd Schneidinger

Friedrich Popp

Rupert Hermann

Gabriele Pestlin

Herbert Von Der Eltz

Hans-Peter Josel

Marie-Ange Buyse

Hans-Georg Batz

Rupert Herrmann

Elke Faatz

Barbara Upmeier

Herbert Andres

Friederike Hesse

Rudolf Vogel

Wolfgang Rollinger

Eloisa Lopez-Calle

Eric Saman

Josef Roedl

Ewelina Hegel

Georg Kurz

Hans-Dieter Jakubke

Frank Bordusa

Joerg Kaufmann

Marisa Kirchenbauer

Stephanie Mueller

Eva Maria Trost-Gross

Hans-Joachim Kytzia

Gerhard Fink

Rene Blind

Raymond A Hui

Erasmus J Huber

Allan Dorn

The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator. Further, the present disclosure relates to devices relating to the methods and kits.

Methods for modulating signal intensity in interaction assays

Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5' to 3&#x2032; direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with an amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture.

IGF-I poly (ethylene glycol) conjugates

The invention relates to a mutated trypsin comprising an amino acid substitution both at position K60 and D189, and at least one more amino acid substitution by histidine at position N143 or position E151. Such trypsin mutant has a preferred cleavage site comprising the amino acids Xaa-Xaa-His, wherein Xaais L, Y or F and Xaais R or K. The invention also relates to a man-made polypeptide comprising a target peptide and the above cleavage site as well as to a method of producing C-terminally modified target peptides by using this mutated trypsin.

C-terminal modification of polypeptides

The invention relates to a process for the production of a biomolecule-linker conjugate of uniform stochiometry. It especially relates to a conjugate consisting of a biomolecule of a molecular weight between 5 kD and 500 kD and a hydrophilic linker molecule said linker having a molecular weight between 1 and 15 kD and between 4 and 60 charged residues, characterized in that said conjugate comprises at least one biomolecule-linker product of uniform stoichiometry in a pre-selected amount.

Conjugates of defined stoichiometry

The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.

Conjugates of mycophenolic acid

A process is disclosed for the production of an antifusogenic peptide by producing a fusion peptide of a length of about 14 to 70 amino acids in a prokaryotic host cell, comprising the steps, under such conditions that inclusion bodies of said fusion peptide are formed, of: (a) expressing in said host cell a nucleic acid encoding said fusion peptide consisting of a first peptide which is an antifusogenic peptide of a length of about 10 to 50 amino acids and a second peptide of a length of about 4 to 30 amino acids, said first peptide being N-terminally linked to said second peptide; (b) cultivating said host cell to produce said inclusion bodies; and (c) recovering said antifusogenic peptide from said inclusion bodies, wherein said recovered antifusogenic peptide consists of said fusion peptide or a peptide comprising the antifusogenic peptide of about 10 to 50 amino acids and which is a fragment cleaved from said fusion peptide. Inclusion bodies of the peptides are disclosed. Also disclosed is a nucleic acid encoding the fusion peptide consisting of a first peptide which is an antifusogenic peptide selected from the group of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and said sequences further consisting of glycine at the C terminal end, N-terminally linked to the second peptide.

Nucleic acids encoding fusion peptides

A process is provided for producing an antifusogenic peptide by producing a fusion peptide of from about 14 amino acids up to 70 amino acids in a prokaryotic host cell under conditions in which inclusion bodies are formed. The antifusogenic peptide recovered from the inclusion bodies is a fragment cleaved from the fusion peptide which comprises an antifusogenic peptide.

Process for making antifusogenic fusion peptides that form inclusion bodies

Conjugates of uncompetitive inhibitors of inosine monophosphate dehydrogenase

The invention concerns a process for diagnosis of an HIV infection by means of an immunoassay using the specific detection of the p24 antigen of HIV1, HIV1-Sub0 and/or the p26 antigen of HIV2, at least one antibody against the env region of HIV1, HIV1-Sub0 and/or of HIV2 and at least one antibody against the pol and/or gag region of HIV1, HIV1-Sub0 and/or HIV2, reagent kits and test strips suitable for diagnostic procedure as well as monoclonal antibodies against p24 and their use.

Method for simultaneous detection of HIV antigens and HIV antibodies

Enzyme inhibition immunoassay

The invention relates to derivatives of hepatitis C virus amino acid sequences. These derivatives can be used to screen samples, such as blood, to determine if antibodies to hepatitis C virus are present.

Specific binding substances for antibodies and their use for immunoassays or vaccines

Compound of the general formula ##STR1## wherein R is an ester-activating group, m and n are identical or different and 0-6, p =0, 2-4, and q and s=1, p=0 if s=0 and p=2-4 if s=1. The compound is novel and suitable for the reproducible coupling of immunological substances at a high yield.

Homobidental, trifunctional linkers used in immunologically active

An immunological method for the determination of triazine and triazine derivatives by a competitive immunoassay in which the sample and labelled atrazine compete for a polyclonal antibody which is bound to a solid phase before, during or after the immunological reaction, the immunological complex binds to the solid phase, the solid phase and unbound labelled atrazine are separated and the label in the solid or liquid phase is determined as a measure of the content of triazine and triazine derivatives, which is characterized in that polyclonal antibodies which were obtained by immunization with a 4-alkylamino-S-triazine are used and a conjugate of a label and 4-amino-S-triazine which is bound to the label via the 6 position is used as the labelled atrazine. Triazine and triazine derivatives can be determined simultaneously using this method.

Immunological detection method for triazines

Compound of the general formula ##STR1## wherein R is an ester-activating group, m and n are identical or different and 0-6, p=0, 2-4, and q and s=1, p=0 if s=0 and p=2-4 if s=1. The compound is novel and suitable for the reproducible coupling of immunological substances at a high yield.

Homobidental, trifunctional linkers, method for their preparation and

Growing community of inventors

Munich, Germany

Eva Hoess